Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 616 | 40% |
| 2020 | 6 | 597 | 43% |
| 2021 | 9 | 781 | 48% |
| 2022 | 14 | 863 | 52% |
| 2023 | 18 | 983 | 56% |
| 2024 | 21 | 1,154 | 59% |
| 2025 from claims | – | 1,028 944–1,088 | 61% |
| 2026 forecast | – | 1,122 988–1,295 | 62% |
| 2027 forecast | – | 1,220 1,043–1,454 | 62% |
| 2028 forecast | – | 1,326 1,106–1,623 | 63% |
| 2029 forecast | – | 1,439 1,176–1,805 | 64% |
| 2030 forecast | – | 1,562 1,251–2,002 | 65% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 60% of the cases CMS names in North Carolina; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 58% hospital outpatient, 36% surgery center, 5% office. The share outside the hospital has moved +42 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center | Office |
|---|---|---|---|
| 2026 · ~1,100 | ~630 | ~440 | ~58 |
| 2027 · ~1,200 | ~670 | ~490 | ~62 |
| 2028 · ~1,300 | ~720 | ~540 | ~66 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 41% (36% in 2025), hospital outpatient about 54% (58% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 60 | 4,698+15%/yr | +15%/yr | 2.0 | 72% | 9,310 in 2030+12%/yr |
| Florida | 65 | 3,941+8.8%/yr | +8.8%/yr | 1.6 | 74% | 5,860 in 2030+6.8%/yr |
| Georgia | 20 | 1,195+14%/yr | +14%/yr | 1.3 | 62% | 2,360 in 2030+12%/yr |
| Tennessee | 23 | 1,041+6.2%/yr | +6.2%/yr | 1.4 | 47% | 2,170 in 2030+13%/yr |
| Oklahoma | 21 | 1,024+2.9%/yr | +2.9%/yr | 2.0 | 28% | 1,160 in 2030+2.1%/yr |
| South Carolina | 17 | 936+18%/yr | +18%/yr | 1.3 | 42% | 2,480 in 2030+18%/yr |
| Arkansas | 21 | 852+4.7%/yr | +4.7%/yr | 2.1 | 57% | 980 in 2030+2.4%/yr |
| Kentucky | 14 | 792+1.1%/yr | +1.1%/yr | 1.6 | 17% | 700 in 2030−2%/yr |
| Maryland | 12 | 704+23%/yr | +23%/yr | 0.8 | 89% | 1,180 in 2030+9%/yr |
| Virginia | 13 | 571−0.7%/yr | −0.7%/yr | 0.5 | 30% | 670 in 2030+2.7%/yr |
| Mississippi | 13 | 445+2.3%/yr | +2.3%/yr | 1.1 | 76% | 590 in 2030+4.7%/yr |
| Louisiana | 4 | 441+6.5%/yr | +6.5%/yr | 1.0 | 46% | 410 in 2030−1.4%/yr |
| Alabama | 6 | 319+4.8%/yr | +4.8%/yr | 0.7 | 49% | 670 in 2030+13%/yr |
| West Virginia | 3 | 158+6.2%/yr | +6.2%/yr | 0.7 | 27% | 100 in 2030−7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 172 | 11,392−0.4%/yr | −0.4%/yr | 10.90.8× | 82% | 12,200 in 2030+1.2%/yr |
| Spinal cord & DRG stimulation | 27 | 1,005−2%/yr | −2%/yr | 0.91.0× | 45% | 950 in 2030−0.9%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Texas
Spr Therapeutics leads with 38% of company spending on these surgeons in 2025, −12 pts on 2024.
In 2025, 11 companies reported engagement with North Carolina’s surgeons worth $168K in consulting, speaking, meals and travel tied to these products, about $8,006 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 64555 (implant neuroelectrodes), commercial plans pay North Carolina’s hospitals a median of $6,286, from $6,286 at the lowest to $10K at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.